SH3KBP1 | OmnibusX

I. Expression across cell types

Name	Number of supported studies	Average coverage
natural killer cell	33 studies	34% ± 10%	Explore
T cell	32 studies	29% ± 9%	Explore
CD8-positive, alpha-beta T cell	31 studies	30% ± 10%	Explore
macrophage	30 studies	29% ± 14%	Explore
CD4-positive, alpha-beta T cell	30 studies	30% ± 7%	Explore
mast cell	26 studies	32% ± 10%	Explore
B cell	25 studies	27% ± 9%	Explore
regulatory T cell	25 studies	36% ± 9%	Explore
classical monocyte	24 studies	33% ± 12%	Explore
pericyte	22 studies	30% ± 11%	Explore
conventional dendritic cell	21 studies	32% ± 18%	Explore
monocyte	20 studies	32% ± 13%	Explore
plasmacytoid dendritic cell	19 studies	35% ± 13%	Explore
mature NK T cell	17 studies	29% ± 7%	Explore
memory B cell	17 studies	22% ± 4%	Explore
naive thymus-derived CD4-positive, alpha-beta T cell	16 studies	26% ± 7%	Explore
non-classical monocyte	16 studies	29% ± 12%	Explore
fibroblast	16 studies	22% ± 6%	Explore
dendritic cell	15 studies	41% ± 14%	Explore
CD16-positive, CD56-dim natural killer cell, human	15 studies	39% ± 9%	Explore
endothelial cell	15 studies	29% ± 12%	Explore
CD16-negative, CD56-bright natural killer cell, human	14 studies	28% ± 6%	Explore
microglial cell	14 studies	52% ± 21%	Explore
mucosal invariant T cell	14 studies	30% ± 8%	Explore
gamma-delta T cell	14 studies	31% ± 11%	Explore
myeloid cell	13 studies	34% ± 14%	Explore
CD8-positive, alpha-beta memory T cell	12 studies	33% ± 11%	Explore
CD4-positive, alpha-beta memory T cell	11 studies	30% ± 9%	Explore
naive thymus-derived CD8-positive, alpha-beta T cell	11 studies	27% ± 5%	Explore
oligodendrocyte precursor cell	11 studies	37% ± 17%	Explore
effector memory CD8-positive, alpha-beta T cell	11 studies	37% ± 6%	Explore
oligodendrocyte	11 studies	40% ± 12%	Explore
naive B cell	10 studies	19% ± 4%	Explore
leukocyte	9 studies	38% ± 19%	Explore
glutamatergic neuron	9 studies	45% ± 23%	Explore
epithelial cell	9 studies	29% ± 10%	Explore
adipocyte	9 studies	54% ± 8%	Explore
GABAergic neuron	8 studies	46% ± 23%	Explore
T follicular helper cell	7 studies	34% ± 7%	Explore
neutrophil	6 studies	26% ± 11%	Explore
effector CD8-positive, alpha-beta T cell	6 studies	31% ± 5%	Explore
interneuron	6 studies	46% ± 25%	Explore
smooth muscle cell	6 studies	21% ± 4%	Explore
innate lymphoid cell	6 studies	23% ± 6%	Explore
retinal cone cell	6 studies	30% ± 6%	Explore
effector memory CD4-positive, alpha-beta T cell	6 studies	30% ± 10%	Explore
type I pneumocyte	6 studies	30% ± 9%	Explore
type II pneumocyte	6 studies	31% ± 6%	Explore
hematopoietic precursor cell	5 studies	41% ± 18%	Explore
neuron	5 studies	32% ± 14%	Explore
lymphocyte	5 studies	42% ± 15%	Explore
plasma cell	5 studies	30% ± 10%	Explore
mononuclear phagocyte	5 studies	29% ± 7%	Explore
effector memory CD8-positive, alpha-beta T cell, terminally differentiated	5 studies	37% ± 10%	Explore
exhausted T cell	4 studies	43% ± 11%	Explore
precursor B cell	4 studies	25% ± 7%	Explore
pro-B cell	4 studies	29% ± 12%	Explore
retinal pigment epithelial cell	4 studies	41% ± 14%	Explore
intermediate monocyte	4 studies	41% ± 22%	Explore
connective tissue cell	4 studies	21% ± 5%	Explore
plasmablast	3 studies	34% ± 13%	Explore
GABAergic interneuron	3 studies	37% ± 0%	Explore
immature B cell	3 studies	20% ± 2%	Explore
germinal center B cell	3 studies	34% ± 4%	Explore
effector CD4-positive, alpha-beta T cell	3 studies	39% ± 7%	Explore
CD4-positive helper T cell	3 studies	26% ± 8%	Explore
granulocyte	3 studies	34% ± 11%	Explore
ciliated cell	3 studies	18% ± 1%	Explore
endothelial cell of lymphatic vessel	3 studies	22% ± 4%	Explore
group 3 innate lymphoid cell	3 studies	38% ± 14%	Explore
T-helper 17 cell	3 studies	30% ± 5%	Explore
astrocyte	3 studies	27% ± 16%	Explore
T-helper 1 cell	3 studies	30% ± 8%	Explore
central memory CD4-positive, alpha-beta T cell	3 studies	30% ± 5%	Explore
central memory CD8-positive, alpha-beta T cell	3 studies	24% ± 7%	Explore
double negative thymocyte	3 studies	42% ± 5%	Explore
CD4-positive, alpha-beta cytotoxic T cell	3 studies	26% ± 10%	Explore
mural cell	3 studies	40% ± 16%	Explore

II. Expression across tissues

Name	Number of supported studies	Average coverage
peripheral blood	16 studies	31% ± 9%	Explore
brain	16 studies	36% ± 19%	Explore
lung	12 studies	23% ± 6%	Explore
bone marrow	4 studies	29% ± 7%	Explore
lymph node	4 studies	25% ± 1%	Explore
liver	4 studies	24% ± 5%	Explore
adipose	4 studies	35% ± 16%	Explore
heart	3 studies	20% ± 2%	Explore
intestine	3 studies	20% ± 3%	Explore

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
thymus	100%	2695.00	651 / 653	100%	34.26	602 / 605
skin	100%	4482.53	1807 / 1809	99%	72.20	466 / 472
breast	100%	4717.86	459 / 459	99%	26.66	1102 / 1118
lung	100%	3935.82	577 / 578	97%	31.52	1126 / 1155
intestine	96%	2374.67	925 / 966	100%	46.40	526 / 527
ovary	93%	1088.40	167 / 180	100%	33.10	430 / 430
uterus	98%	1499.58	166 / 170	95%	26.53	434 / 459
kidney	100%	1624.62	89 / 89	92%	22.60	825 / 901
stomach	90%	1160.16	324 / 359	99%	43.47	284 / 286
bladder	95%	1500.00	20 / 21	90%	33.25	456 / 504
brain	85%	2511.73	2257 / 2642	100%	34.54	705 / 705
adrenal gland	92%	1275.57	237 / 258	90%	19.92	206 / 230
esophagus	78%	1086.47	1120 / 1445	92%	30.98	168 / 183
prostate	86%	1094.14	210 / 245	81%	9.29	406 / 502
liver	54%	526.97	122 / 226	88%	15.19	356 / 406
pancreas	11%	99.58	36 / 328	98%	43.56	174 / 178
adipose	100%	5743.31	1204 / 1204	0%	0	0 / 0
lymph node	0%	0	0 / 0	100%	87.73	29 / 29
peripheral blood	100%	11157.96	929 / 929	0%	0	0 / 0
spleen	100%	4095.12	241 / 241	0%	0	0 / 0
eye	0%	0	0 / 0	98%	19.78	78 / 80
heart	96%	2303.20	825 / 861	0%	0	0 / 0
blood vessel	94%	1646.24	1257 / 1335	0%	0	0 / 0
tonsil	0%	0	0 / 0	93%	23.47	42 / 45
muscle	37%	369.31	299 / 803	0%	0	0 / 0
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
gingiva	0%	0	0 / 0	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0
ureter	0%	0	0 / 0	0%	0	0 / 1

III. Associated gene sets

GO_0050871	Biological process	positive regulation of B cell activation
GO_0006897	Biological process	endocytosis
GO_0007010	Biological process	cytoskeleton organization
GO_0007267	Biological process	cell-cell signaling
GO_0007015	Biological process	actin filament organization
GO_0006915	Biological process	apoptotic process
GO_0008360	Biological process	regulation of cell shape
GO_0016477	Biological process	cell migration
GO_0005856	Cellular component	cytoskeleton
GO_0005886	Cellular component	plasma membrane
GO_0030139	Cellular component	endocytic vesicle
GO_0043005	Cellular component	neuron projection
GO_0005925	Cellular component	focal adhesion
GO_0005911	Cellular component	cell-cell junction
GO_0005829	Cellular component	cytosol
GO_0045202	Cellular component	synapse
GO_0005737	Cellular component	cytoplasm
GO_0030659	Cellular component	cytoplasmic vesicle membrane
GO_0031625	Molecular function	ubiquitin protein ligase binding
GO_0005515	Molecular function	protein binding
GO_0017124	Molecular function	SH3 domain binding

IV. Literature review

[source]

Gene name	SH3KBP1
Protein name	SH3 domain-containing kinase-binding protein 1 (CD2-binding protein 3) (CD2BP3) (Cbl-interacting protein of 85 kDa) (Human Src family kinase-binding protein 1) (HSB-1) Alternative protein SH3KBP1 SH3 domain containing kinase binding protein 1
Synonyms	CIN85
Description	FUNCTION: Adapter protein involved in regulating diverse signal transduction pathways. Involved in the regulation of endocytosis and lysosomal degradation of ligand-induced receptor tyrosine kinases, including EGFR and MET/hepatocyte growth factor receptor, through an association with CBL and endophilins. The association with CBL, and thus the receptor internalization, may be inhibited by an interaction with PDCD6IP and/or SPRY2. Involved in regulation of ligand-dependent endocytosis of the IgE receptor. Attenuates phosphatidylinositol 3-kinase activity by interaction with its regulatory subunit (By similarity). May be involved in regulation of cell adhesion; promotes the interaction between TTK2B and PDCD6IP. May be involved in the regulation of cellular stress response via the MAPK pathways through its interaction with MAP3K4. Is involved in modulation of tumor necrosis factor mediated apoptosis. Plays a role in the regulation of cell morphology and cytoskeletal organization. Required in the control of cell shape and migration. Has an essential role in the stimulation of B cell activation . .
Accessions	ENST00000699732.1 A0A8V8TNP2 ENST00000699720.1 A0A8V8TP40 ENST00000699724.1 A0A8V8TNW8 ENST00000379726.8 ENST00000699675.1 Q5JPT2 ENST00000699678.1 ENST00000699729.1 ENST00000699725.1 ENST00000699674.1 ENST00000699738.1 A0A8V8TQC9 A0A8V8TNP7 A0A8V8TNU1 ENST00000699723.1 [Q96B97-2] ENST00000379716.5 [Q96B97-3] A0A8V8TNL0 A0A8V8TPZ1 ENST00000699734.1 ENST00000699669.1 A0A8V8TQ02 ENST00000699679.1 A0A8V8TQG3 ENST00000699672.1 ENST00000699670.1 Q96B97 ENST00000494961.6 ENST00000699742.1 ENST00000379698.8 [Q96B97-2] A0A8V8TP69 ENST00000699726.1 ENST00000699731.1 ENST00000699727.1 L0R6P6 A0A8V8TNT5 ENST00000699667.1 A0A8V8TQD8 A0A8V8TP39 ENST00000699671.1 ENST00000699676.1 A0A8V8TQF6 A0A8V8TNL8 A0A8V8TP63 A0A8V8TPM1 ENST00000699721.1 ENST00000699733.1 ENST00000699730.1 A0A8V8TNS8 A0A8V8TP33 A0A8V8TP27 A0A8V8TQU1 ENST00000699673.1 ENST00000397821.8 [Q96B97-1] ENST00000699735.1 ENST00000699666.1 ENST00000699668.1

SH3KBP1 report

I. Expression across cell types

II. Expression across tissues

III. Associated gene sets

IV. Literature review